SCHEMBL4676932

SCHEMBL4676932

O=C(Cc1cocc1Oc1cccc(C(F)(F)F)c1)C(=O)c1nc[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
POLB P06746 2/20 0.37
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ICAM1 P05362 1/20 0.36
SELE P16581 1/20 0.36
MAOB P27338 1/20 0.36
AOC3 Q16853 1/20 0.36
MAPT P10636 1/20 0.36
SCN9A Q15858 1/20 0.35
BRAF P15056 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
KDR P35968 1/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674605 0.88 ALDH1A1 (0.37) THRBALDH1A1ICAM1SELEMAOB
SCHEMBL4672413 0.85 MEN1 (0.40) KDM4EPOLBALDH1A1L3MBTL1MAPT
SCHEMBL4672499 0.85 LMNA (0.35) ICAM1SELE
SCHEMBL4673542 0.85 CAMK2A (0.34) KDM4EALDH1A1L3MBTL1BRAFKMT2A
SCHEMBL4676764 0.83 KDM4E (0.41) KDM4ETHRATHRBPOLBALDH1A1
SCHEMBL4672941 0.83 KDM4E (0.41) KDM4EPOLBALDH1A1L3MBTL1MAOB
SCHEMBL4671513 0.83 KDM4E (0.41) KDM4ETHRATHRBPOLBALDH1A1
SCHEMBL4677638 0.82 MPO (0.38) ALDH1A1MAOBMAPTKMT2AMEN1
SCHEMBL4678501 0.82 KDM4E (0.42) KDM4ETHRATHRBPOLBALDH1A1
SCHEMBL4676489 0.82 KDM4E (0.42) KDM4EPOLBALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDM4E 947/4885THRA 627/4885THRB 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.